Various small molecular proteins that induce changes in cell conformation also affect key downstream signaling pathways, such as the overactivation of the HER2-SHCBP1-PLK1 axis by SHC linker protein 1 (SHC1), representing a novel mechanism of cancer resistance to trastuzumab. Here, PLK1 is linked to cancer.